

EGETIS THERAPEUTICS

PRESS RELEASE

Egetis Therapeutics AB
Stockholm, Sweden, Oct 25, 2021

CEO and Chairman of the Board in Egetis Therapeutics acquire shares

Egetis Therapeutics AB (publ) (ticker: EGTX) today announced that Nicklas Westerholm, CEO, and Thomas Lönngren, Chairman of the Board, have acquired shares in the company.

Nicklas Westerholm has acquired 50,933 additional shares, and Thomas Lönngren has acquired 65,129 additional shares. Nicklas Westerholm's total holding now amount to 109,873 in addition to warrants and employee stock options. Thomas Lönngren's total holding now amount to 165,129 shares.

For further information, please contact:

Nicklas Westerholm, CEO, Egetis Therapeutics
Tel. +46 (0)73 354 20 62
Email: nicklas.westerholm@egetis.com

The information was submitted for publication, through the agency of the contact person set out above, at 2021-11-25, 08:00 CET.

About Egetis Therapeutics

Egetis Therapeutics is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious diseases with significant unmet medical needs in the orphan drug segment. The drug candidate Emcitate is developed as the first potential treatment for patients with MCT8 deficiency, a rare disease with high unmet medical need and no available treatment. A Phase IIb clinical trial has been completed with significant and clinically relevant effects. A Phase IIb/III early intervention study has been initiated with the first patient dosed in Dec 2020. Emcitate holds Orphan Drug Designation (ODD) in the US and EU and has been granted Rare Pediatric Disease Designation and Fast Track Designation by the US FDA. The drug candidate Aladote is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol poisoning. A proof of principle study has been successfully completed and the design of the upcoming pivotal Phase IIb/III study for Aladote has been finalized after completed interactions with FDA, EMA and MHRA. Aladote has been granted Orphan Drug Designation in the US and an application for ODD was submitted in Europe in Q1 2021. There is an ongoing dialogue with EMA on the appropriate indication for an ODD in the EU.

Egetis Therapeutics (STO: EGTX) is listed on the Nasdaq Stockholm main market. For more information, see www.egetis.com